Novo Nordisk Shares Face Pressure Amid Pricing Concerns and Analyst Caution

Novo Nordisk finds itself navigating multiple challenges simultaneously. The company's stock recently touched a fresh 52-week low, an event that coincided with its shares trading ex-dividend. This sustained downward trend points to deeper issues beyond short-term selling pressure.

Pipeline and Shareholder Meeting Offer Some Balance

At the Annual General Meeting held on March 26, shareholders elected three new members to the board of supervisors: Helena Saxon, Jan van de Winkel, and Ramona Sequeira. Poul Weihrauch is set to join initially as an observer, with a proposal for his election as a full member scheduled for 2027. Additionally, investors approved a share buyback authorization for up to 10 percent of the company's share capital.

Newly appointed CEO Mike Doustdar is looking to the development pipeline to drive future growth. The company is pinning medium-term hopes on several assets, including CagriSema, the hemophilia therapy Mim8, and Phase 3 data for etavopivat in sickle cell disease and ziltivekimab in chronic kidney disease. The stock currently trades at approximately ten times earnings—a valuation that appears moderate considering the setbacks of recent months.

The dividend for 2025 has been increased by 2.6 percent to 11.70 DKK per share, with a payout ratio of 50.7 percent. The payment date is set for April 8.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Revenue Warning Triggered by Intense Pricing Pressure

The core of Novo Nordisk's current difficulties is a significant reduction in its sales forecast for the current year. The primary driver is a pricing agreement with the U.S. government that has substantially lowered costs for Wegovy and Ozempic. Through a direct consumer channel, the price has been slashed from over $1,000 per month to $350. This deal is putting considerable strain on the GLP-1 drug segment. When the revised outlook was announced earlier this year, the stock plummeted 18 percent.

The situation has shown little improvement since then. The share price now sits roughly 31 percent below its 200-day moving average, underscoring the depth of the erosion in investor confidence.

Divergent Views from Market Experts

Analyst sentiment provides little comfort. Bernstein analyst Justin Smith initiated coverage with an Underperform rating and a price target of 175 DKK. He argues that the earnings downgrade cycle is not yet over, citing key risks such as declining market share for Ozempic and Wegovy, alongside the looming U.S. patent expiration for semaglutid by 2032.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

TD Cowen downgraded the equity from Buy to Hold, simultaneously cutting its price target to $42. While the bank acknowledges stabilizing factors like the ongoing 15 billion DKK share repurchase program and a distribution agreement with Hims & Hers, it believes the structural risks in the GLP-1 market are more significant.

Overall, the consensus remains cautious. Out of 24 analysts covering the stock, 19 assign a Hold rating, four recommend a Buy, and one advises Selling. The average price target stands at $65.56, which remains substantially above the current trading level.

Ad

Novo Nordisk Stock: New Analysis - 31 March

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

DK0062498333 | NOVO | boerse | 69032874 |